Navinci (formerly Olink Bioscience), has a proud history of inventing analytic technologies for nucleic acids and proteins, identifying commercial opportunities and bringing successful products to the market to serve scientist in research and drug development. Founded in 2004 on the breakthrough innovations by Ulf Landegren and colleagues at Uppsala University, the company has directly marketed a wide range of products including the Duolink in situ protein detection product line, which was acquired by Sigma-Aldrich in 2016.
Navinci has also launched several daughter companies such as Olink Proteomics (noted on Nasdaq, New York) for high-throughput protein analysis in blood, Q-linea (noted on Nasdaq) focusing on counteracting antibiotic resistance in sepsis, and Halogenomics (acquired by Agilent) in target selection for next generation sequencing. Moreover, the company has outlicensed IP rights to several leading international life science companies. Navinci holds a broad and growing patent portfolio utilizing oligonucleotide-conjugated antibodies for detection of proteins and their interactions.
From our base in Uppsala, Sweden, Navinci contributes to improve human health by serving scientist with sharp and tailored tools to study proteins and their interactions in order to understand human biology and develop better drugs.